• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

The Emergence of Medical Affairs in Biopharma


Pharmaceutical Executive

The role of medical affairs organizations within the biopharma industry is evolving, with these functions providing increasing patient and physician-centered services as part of a new business model aimed at delivering value in healthcare. Honorio Silva, MD, President-Elect of the International Federation of Associations of Pharmaceutical Physicians (IFAPP) and VP of ACRES, the Alliance for Clinical Research Excellence and Safety, will be chairing a panel on this topic at DIA’s upcoming 51st Annual Meeting in Washington, DC.

In previewing the session, Pharm Exec spoke with Silva about the key factors driving growth in the medical affairs field, the challenges for teams in providing true value-added services, and the new expectations medical affairs personnel must meet amid the explosion of digital health and the growing demand for data transparency.

Related Content